Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
暂无分享,去创建一个
A. Sapino | A. Pisacane | L. Gammaitoni | M. Aglietta | G. Grignani | D. Sangiolo | Lidia Giraudo | E. Fiorino | V. Leuci | R. Rotolo | G. Mesiano | Y. Pignochino | L. D'ambrosio | Sara Butera | F. Capozzi | M. Basiricò | L. Giraudo | Chiara Salfi | L. D'Ambrosio
[1] H. Stepanyan,et al. Intraventricular Undifferentiated Pleomorphic Sarcoma: A Case Report , 2016, Cureus.
[2] Zhaoming Ye,et al. T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities , 2016, Front. Immunol..
[3] R. Ferris,et al. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. , 2016, Oral oncology.
[4] Y. Linn,et al. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts , 2016, Cancer Immunology, Immunotherapy.
[5] Robert A. Smith,et al. Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. , 2015, Experimental cell research.
[6] C. Coch,et al. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC) , 2015, Journal of Cancer Research and Clinical Oncology.
[7] A. Dubrovska,et al. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. , 2015, Seminars in cancer biology.
[8] Narasimhan P. Agaram,et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. , 2015, Human pathology.
[9] J. Kaiser. The cancer stem cell gamble. , 2015, Science.
[10] Sadik H. Kassim,et al. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.
[11] J. Medema,et al. Cancer stem cells – important players in tumor therapy resistance , 2014, The FEBS journal.
[12] Chin-Shang Li,et al. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma , 2014, BMC Cancer.
[13] Z. Duan,et al. Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential , 2014, Oncoimmunology.
[14] Ș. Purcaru,et al. Cancer Stem Cells: Biological Functions and Therapeutically Targeting , 2014, International journal of molecular sciences.
[15] D. Tang,et al. Cancer stem cells and radioresistance , 2014, International journal of radiation biology.
[16] C. Fletcher,et al. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition , 2014, Pathology.
[17] K. Jang,et al. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas , 2013, PloS one.
[18] F. Dammacco,et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.
[19] T. Venesio,et al. Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features , 2013, Clinical Cancer Research.
[20] O. H. Iwenofu,et al. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms , 2013, Modern Pathology.
[21] R. Maki,et al. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma , 2013, Sarcoma.
[22] Robin L. Jones,et al. NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma , 2012, Cancer.
[23] Robin L. Jones,et al. NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine , 2012, PloS one.
[24] M. Chintagumpala,et al. Targeted Therapy in Bone and Soft Tissue Sarcoma in Children and Adolescents , 2012, Current Oncology Reports.
[25] M. van Glabbeke,et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. , 2011, European journal of cancer.
[26] A. D. Dei Tos,et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] B. Seliger,et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer , 2010, Cancer Immunology, Immunotherapy.
[28] A. Contento,et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial , 2009, Hematological oncology.
[29] T. Heare,et al. Bone tumors: osteosarcoma and Ewing's sarcoma. , 2009, Current opinion in pediatrics.
[30] A. Allan,et al. Cancer stem cells: implications for the progression and treatment of metastatic disease , 2007, Journal of cellular and molecular medicine.
[31] L. Koniaris,et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. , 2007, The Journal of surgical research.
[32] M. Clarke,et al. Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.
[33] M. Semik,et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] W. Cui,et al. Stably Transfected Human Embryonic Stem Cell Clones Express OCT4‐Specific Green Fluorescent Protein and Maintain Self‐Renewal and Pluripotency , 2005, Stem cells.
[35] Robert S Negrin,et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. , 2004, Blood.
[36] R. Negrin,et al. Studies of ex Vivo Activated and Expanded CD8+ NK-T Cells in Humans and Mice , 2002, Journal of Clinical Immunology.
[37] S. Ferrari,et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] B. Seliger,et al. HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.
[39] M. Ladanyi,et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 , 2001, International journal of cancer.
[40] R. Negrin,et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. , 2001, Blood.
[41] S. Ferrari,et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] L. Ailles,et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.
[43] D. Huhn,et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma , 1999, British Journal of Cancer.
[44] D. Hicklin,et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. , 1999, The American journal of pathology.
[45] D. Trono,et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.
[46] D. Trono,et al. A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.
[47] F. Garrido,et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.
[48] F. Marincola,et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.
[49] R. Negrin,et al. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. , 1994, Journal of immunology.
[50] D. Huhn,et al. Propagation of large numbers of T cells with natural killer cell markers , 1994, British journal of haematology.
[51] J. Roth,et al. Five‐year survival after pulmonary metastasectomy for adult soft tissue sarcoma , 1992, Cancer.
[52] I. Weissman,et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.
[53] P. Casali,et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. , 2015, The Lancet. Oncology.
[54] A. Bertotti,et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. , 2014, Cancer research.
[55] P. Casali,et al. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] A. Sapino,et al. Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells Running title: CIK cells kill autologous chemo-surviving melanoma CSCs , 2022 .